| Abbott Laboratories, F. Hoffmann-La Roche AG, Haemonetics Corporation, HemoSonics
Market research report determines the increase in changes and the aspects which are likely to have an impact on the growth of the Global Point of Care Coagulation Testing Devices Market. Moreover, increased demand for the technologies is also one of the factors, which are likely to boost the growth of the market research industry. The market research study uses several tools and techniques which are used for the determination of the growth of the global Point of Care Coagulation Testing Devices market. Moreover, increased demand for the factors influencing the growth of the market is also one of the major aspects which is likely covered in depth in the report. It also focuses and highlights the strategies and the trends, in which the manufacturer and the company is likely to move. Request a sample to obtain authentic analysis and comprehensive market insights @ https://www.thebrainyinsights.com/enquiry/sample-request/12648
The research study is also known to provide in depth analysis of the reports which is one of the key aspects for the growth of the global Point of Care Coagulation Testing Devices market. The report is also used in the analysis of the growth rates and the threats of new entrants, which are used for the determination of the growth of the market for the estimated forecast period. One of the methods for the determination of the growth of the market is the increased use of the statistical tools, which is used for the estimation of the growth of the market for the estimated forecast period. The study covers the production, sales, and revenue of various top players in the global Point of Care Coagulation Testing Devices market, therefore enabling customers to achieve thorough information of the competition and henceforth plan accordingly to challenge them head on and grasp the maximum market share. This report is filled with significant statistics and information for the consumers to attain in-depth data of the Point of Care Coagulation Testing Devices and further Point of Care Coagulation Testing Devices growth. The up-to-date, complete product knowledge, end users, industry growth will drive the profitability and revenue. Point of Care Coagulation Testing Devices report studies the current state of the market to analyze the future opportunities and risks. Point of Care Coagulation Testing Devices report provides a 360-degree global market state. Primarily, the report delivers Point of Care Coagulation Testing Devices introduction, overview, market objectives, market definition, scope, and market size valuation. Top Leading Companies:
Abbott Laboratories,F. Hoffmann-La Roche AG,Haemonetics Corporation,HemoSonics,Koninklijke Philips N.V.,LLC,Medtronic plc,Micropoint Bioscience, Inc,Siemens Healthineers,Sienco, Inc.,Werfen
Discover more about report analysis with figures and data tables, along with the table of contents@ https://www.thebrainyinsights.com/report/point-of-care-coagulation-testing-devices-market-12648
Market Summary:
Anticoagulation Monitoring Devices
Home Care
Others
The study also provides detailed analysis of the market, which consists of the growth of the regions, which is one of the major aspects which is likely to have an impact on the market. The strengths and the political factors, which are likely to affect the market is also covered in detail for the estimation of the market in the estimated forecast. In addition, the political and the environmental factors are also determined affecting the global keyword market in the estimated forecast period. Segment type is also an important aspect of any market research study. Reports are product based, they also includes information on sales channel, distributors, traders and dealers. This helps in efficient planning and execution of supply chain management as it drastically affects the overall operations of any business. The Brainy Insights’s analysts constantly monitor the industry impacts of current events in real-time – here is an update of how this industry is likely to be impacted as a result of the global COVID-19 pandemic:
Although the COVID-19 (coronavirus) pandemic threatened revenue for the Point of Care Coagulation Testing Devices industry in early 2020 as corporate profit and advertising expenditure fell, a surge in coronavirus-related press releases as well as stock market activity boosted demand for industry services in late 2020 and over 2021. Despite falling demand from some downstream markets, demand from government entities and healthcare providers has increased to disseminate vital information about the virus. Technological advancement among industry operators has surged as they seek more streamlined access to coronavirus information for consumers. We Offer tailor-made Solutions to fit Your Requirements, Request Customization @ https://www.thebrainyinsights.com/enquiry/request-customization/12648
About The Brainy Insights:
The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients’ objectives of high-quality output within a short span of time. We provide both customized (clients’ specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients’ requirement whether they are looking to expand or planning to launch a new product in the global market. Contact Us

Point of Care Coagulation Testing Devices Market to Eyewitness Massive Growth by 2028 | Abbott Laboratories, F. Hoffmann-La Roche AG, Haemonetics Corporation, HemoSonics

Download
Quantra QPlus System: Quantra Hemostasis Analyzer, QPlus Cartridge. (Photo: Business Wire)
January 19, 2021 12:54 PM Eastern Standard Time
CHARLOTTESVILLE, Va.--( BUSINESS WIRE )--HemoSonics welcomes the January 14th guidance of the US Food and Drug Administration (FDA) that broadens the use of viscoelastic coagulation analyzers for hospital patient healthcare settings in response to COVID-19. The FDA guidance is intended, for the duration of the COVID-19 public health emergency, to expand the availability of coagulation systems for measurement of whole blood viscoelastic properties to assess hemostasis.1
HemoSonics’s flagship product, the Quantra Hemostasis Analyzer , with its QPlus® cartridge, represents the only viscoelastic coagulation testing (VET) system specifically designed and optimized for rapid and easy operation in point-of-care (POC) settings, such as operating rooms, Emergency Departments, or intensive care units. The Quantra system’s innovative closed-cartridge design requires no open-tube blood manipulation after sample collection. The Quantra system is FDA cleared (de novo) for POC use, which may help to minimize the flow of traffic with sample transporters and/or operators in and out of units designated for the care of COVID-19 patients. “The Quantra System’s intuitive operation and easy-to-interpret Dials display may help streamline what is otherwise a complex process of coagulation testing,” said Bob Roda, CEO of HemoSonics. “The QPlus cartridge provides multiple whole blood coagulation parameters within 15 minutes or less, helping clinicians to make quicker, more informed treatment decisions that support better patient outcomes.”
Hypercoagulability, an abnormally increased risk for blood clotting, has been observed in patients with COVID-19.2 Clinical reports have shown that in patients with severe COVID-19 infection, blood clotting abnormalities are likely triggered by the acute inflammatory response.3-7
HemoSonics has advocated for the use of viscoelastic whole blood testing as a tool in the diagnosis and management of COVID-19 patients, consistent with its mission to provide efficient, easy-to-use tools that improve patient care. Since the onset of the global pandemic, HemoSonics has supported several clinical sites in Europe and the US in their quest to understand the potential utility of the Quantra system for the evaluation of coagulation status in COVID-19 patients at the POC setting:7
“The Quantra is the only device on which we can operate safely without needing specialized rooms and a biohazard cabinet.”
– Ekaterina Baryshnikova, PhD, IRCCS Policlinico San Donato, Milan, Italy
The Quantra system’s innovative ultrasound technology, proprietary closed-cartridge design, unparalleled ease of use, and ease of interpretation make it uniquely suited for use in critical or emergency care settings with COVID-19 patients. For more information on the Quantra QPlus System, email contact@hemosonics.com or visit www.HemoSonics.com . Disclaimer
This communication contains information on products which is targeted to a wide range of audiences and could contain product details or information not otherwise accessible or valid in your country. Please refer to the applicable approved instructions for use. About HemoSonics
HemoSonics is a medical device company with the primary mission to deliver clinical tools that provide actionable information in the critical care settings, resulting in better care for patients and lower overall medical costs. The Quantra® Hemostasis Analyzer, the flagship product of HemoSonics, is designed to improve patient outcomes and reduce healthcare costs by providing unique and optimized coagulation information, for easy and fast interpretation and simple, more efficient point-of-care bleeding management workflows. HemoSonics is headquartered in Charlottesville, VA, with research, development and manufacturing facilities in Durham, NC. HemoSonics is part of the Stago group, a leading company in the in vitro diagnostics industry dedicated to the exploration of thrombosis and hemostasis. References:
1. US Food and Drug Administration. Coagulation Systems for Measurement of Viscoelastic Properties: Enforcement Policy During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency: Guidance for Industry and Food and Drug Administration Staff, January 2021. Available at: https://www.fda.gov/media/145135/download . 2. Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html . 3. Han H, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120. doi: 10.1515/cclm-2020-0188. 4. Tang N, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-47. 5. Darzi AJ, et al. Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood. 2020 May 14;135(20):1788-1810. doi: 10.1182/blood.2019003603. 6. Hunt B, et al. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. https://thrombosisuk.org/covid-19-thrombosis.php . 7. Ranucci M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020 Jul;18(7):1747-1751. doi: 10.1111/jth.14854. Contacts

HemoSonics Welcomes FDA Support of Viscoelastic Coagulation Analyzers for COVID-19 Patients; Highlights the Benefits of the Quantra® Hemostasis Analyzer

September 09, 2020 02:36 PM Eastern Daylight Time
CHARLOTTESVILLE, Va.--( BUSINESS WIRE )--HemoSonics announced today that its Quantra Desktop Remote Viewer Software (QDRV) has received a 510(k) clearance from the FDA. The QDRV enables remote access to its flagship product, the Quantra QPlus System. The Quantra System provides rapid, actionable coagulation results at the point of care – now viewable from anywhere in the hospital, giving clinicians the opportunity to make informed bleeding management decisions when time is critical. Based on an innovative ultrasound technology (SEER – Sonic Evaluation of Elasticity via Resonance), the Quantra System is revolutionizing point-of-care viscoelastic testing (VET) efficiency by combining rapid results, ease of interpretation, and simple intuitive operation. The Quantra Desktop Remote Viewer is a PC application that allows clinicians to see near real-time screens of any Quantra analyzer in their network. “Managing acute bleeding in perioperative situations is a team effort, requiring rapid, accurate hemostasis results,” said Bob Roda, President and Chief Executive Officer of HemoSonics. “The Quantra Desktop Remote Viewer enhances the revolutionary point-of-care efficiency of the Quantra System, allowing secure and rapid access to results regardless of where the instrument is located – in the operating room, ICU, or laboratory.”
Key Benefits and Features of the Quantra Desktop Remote Viewer:
Support patient blood management initiatives with widespread access to results and assist clinicians in their strategies to optimize blood product utilization. Get Actionable Information Quickly: Remotely view accurate live and historical whole blood coagulation information from any networked Quantra analyzer. View easy-to-interpret Quantra dials, trends, and curve screens, and history for all tests per device. Go Organization-Wide: Display on monitors in your operating room, or on Windows® workstations facility-wide. Simplify Data Collection: Export results (screens and case history) easily within your secure network; facilitate clinical research and peer review. Hospital-grade encryption and security; meets HIPAA/HITECH requirements. Availability
The Quantra QPlus System, comprising a Quantra Hemostasis Analyzer, QPlus cartridge, Level 1 and 2 Quality Controls, and now QDRV, is cleared for sale in the United States. The Quantra System and its QPlus and QStat™ cartridges, respective quality controls, and QDRV software are commercially available in Europe and select countries worldwide. In the United States, the QStat Cartridge is available for investigational use only. About HemoSonics
HemoSonics is a medical device company with the primary mission to deliver clinical tools that provide actionable information in critical care settings, resulting in better care for patients and lower overall medical costs. The Quantra Hemostasis Analyzer, the flagship product of HemoSonics, is designed to improve patient outcomes and reduce healthcare costs by providing unique and optimized coagulation information, for easy and fast interpretation and simple, more efficient point-of-care bleeding management workflows. HemoSonics is headquartered in Charlottesville, VA, with research, development and manufacturing facilities in Durham, NC. For more information, visit www.hemosonics.com . HemoSonics is part of the Stago group, a leading company in the in vitro Diagnostics industry dedicated to the exploration of thrombosis and hemostasis. Contacts

HemoSonics Adds Remote Viewer to its Quantra® QPlus® System, Bringing Rapid Results to Clinicians Anywhere in the Hospital

Copley Consulting Group helps organizations drive business transformation.On July 19th, 2021, Copley Consulting Group was acquired by The Judge Group. The terms of the transaction were not disclosed.

Copley Consulting Group

February 26 , 2019 -- HemoSonics , a manufacturer of diagnostic platforms for critical bleeding , has selected The Copley Consulting Group 's FDA Solution based on the Infor CloudSuite ™ Industrial Enterprise Resource Planning application .

HemoSonics Selects The Copley Consulting Group and Infor ERP to Meet Regulatory Compliance.

Cambridge Consultants leads the way in innovative product development. The company is the development partner of choice to many of the world's leading blue chips, as well as the virtual development team for ambitious start-up companies.

Cambridge Consultants

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Medical Devices

Health IT 

HemoSonics is a medical device company founded to develop and bring to market diagnostics to quantify and characterize the hemostatic potential of whole blood. The company's mission is to save lives and improve the quality of life while reducing costs through the use of our products in all applicable clinical settings. The company's products combine a flexible test device with targeted disposable test chambers to diagnose specific defects of hemostasis and inform appropriate therapy. This approach makes its system easier to operate and interpret than existing products. Potential clinical applications include trauma, cardiovascular procedures, organ transplantation, orthopedic surgery, neurological surgery, and labor and delivery among others.

Name	Title	Status
Timothy J Fischer	Chief Executive Officer	Current
William F Walker	Chief Technology Officer	Current
Francesco Viola	Chief Security Officer	Current

Name	Timothy J Fischer	William F Walker	Francesco Viola
Work History
Title	Chief Executive Officer	Chief Technology Officer	Chief Security Officer
Status	Current	Current	Current

Wells Fargo Success Story

3M Success Story

Platform Overview

HemoSonics

Executives

HemoSonics Management Team

3 Team Members

Discover the right solution for your team